Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Collegium Pharmaceutical (COLL) Common Equity (2016 - 2026)

Collegium Pharmaceutical has reported Common Equity over the past 11 years, most recently at $301.7 million for Q4 2025.

  • For Q4 2025, Common Equity rose 31.83% year-over-year to $301.7 million; the TTM value through Dec 2025 reached $301.7 million, up 31.83%, while the annual FY2025 figure was $301.7 million, 31.83% up from the prior year.
  • Common Equity for Q4 2025 was $301.7 million at Collegium Pharmaceutical, up from $274.8 million in the prior quarter.
  • Over five years, Common Equity peaked at $301.7 million in Q4 2025 and troughed at $170.0 million in Q1 2021.
  • A 5-year average of $218.1 million and a median of $209.8 million in 2021 define the central range for Common Equity.
  • Biggest five-year swings in Common Equity: skyrocketed 62.46% in 2021 and later decreased 21.91% in 2022.
  • Year by year, Common Equity stood at $202.9 million in 2021, then fell by 3.98% to $194.8 million in 2022, then increased by 0.3% to $195.4 million in 2023, then increased by 17.1% to $228.8 million in 2024, then soared by 31.83% to $301.7 million in 2025.
  • Business Quant data shows Common Equity for COLL at $301.7 million in Q4 2025, $274.8 million in Q3 2025, and $232.2 million in Q2 2025.